These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 24768264)

  • 1. Therapeutic drug monitoring of intracellular anti-infective agents.
    D'Avolio A; Pensi D; Baietto L; Di Perri G
    J Pharm Biomed Anal; 2014 Dec; 101():183-93. PubMed ID: 24768264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The intracellular pharmacology of antiretroviral protease inhibitors.
    Ford J; Khoo SH; Back DJ
    J Antimicrob Chemother; 2004 Dec; 54(6):982-90. PubMed ID: 15537695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug monitoring of antiretroviral agents scenario.
    Moltó J; Clotet B
    J HIV Ther; 2004 Nov; 9(4):75-8. PubMed ID: 15731738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic drug monitoring of anti-infective agents in critically ill patients.
    Jager NG; van Hest RM; Lipman J; Taccone FS; Roberts JA
    Expert Rev Clin Pharmacol; 2016 Jul; 9(7):961-79. PubMed ID: 27018631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring and the inhibitory quotient of antiretroviral drugs: can they be applied to the current situation?
    Ribera E; López-Cortés LF; Soriano V; Casado JL; Mallolas J
    Enferm Infecc Microbiol Clin; 2005 Jul; 23 Suppl 2():41-67. PubMed ID: 16373004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals.
    Almond LM; Hoggard PG; Edirisinghe D; Khoo SH; Back DJ
    J Antimicrob Chemother; 2005 Oct; 56(4):738-44. PubMed ID: 16141277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemia.
    De Francia S; DʼAvolio A; Ariaudo A; Pirro E; Piccione F; Simiele M; Fava C; Calcagno A; Di Perri G; Saglio G
    Ther Drug Monit; 2014 Jun; 36(3):410-2. PubMed ID: 24342895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients?
    Colombo S; Telenti A; Buclin T; Furrer H; Lee BL; Biollaz J; Decosterd LA;
    Ther Drug Monit; 2006 Jun; 28(3):332-8. PubMed ID: 16778716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients.
    Crommentuyn KM; Mulder JW; Mairuhu AT; van Gorp EC; Meenhorst PL; Huitema AD; Beijnen JH
    Antivir Ther; 2004 Oct; 9(5):779-85. PubMed ID: 15535416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals.
    Almond LM; Edirisinghe D; Dalton M; Bonington A; Back DJ; Khoo SH
    Clin Pharmacol Ther; 2005 Aug; 78(2):132-42. PubMed ID: 16084848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The value of plasma antiretroviral drug monitoring in the management of HIV infected patients].
    Tréluyer JM
    Ann Med Interne (Paris); 2000 Jun; 151(4):291-6. PubMed ID: 10922957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A strategy for liquid chromatography/tandem mass spectrometric assays of intracellular drugs: application to the validation of the triphosphorylated anabolite of antiretrovirals in peripheral blood mononuclear cells.
    Becher F; Pruvost A; Gale J; Couerbe P; Goujard C; Boutet V; Ezan E; Grassi J; Benech H
    J Mass Spectrom; 2003 Aug; 38(8):879-90. PubMed ID: 12938109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic drug monitoring in cancer--are we missing a trick?
    Bardin C; Veal G; Paci A; Chatelut E; Astier A; Levêque D; Widmer N; Beijnen J
    Eur J Cancer; 2014 Aug; 50(12):2005-9. PubMed ID: 24878063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical benefit of interventions driven by therapeutic drug monitoring.
    Rendón A; Núñez M; Jiménez-Nácher I; González de Requena D; González-Lahoz J; Soriano V
    HIV Med; 2005 Sep; 6(5):360-5. PubMed ID: 16156885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference.
    Wallemacq P; Armstrong VW; Brunet M; Haufroid V; Holt DW; Johnston A; Kuypers D; Le Meur Y; Marquet P; Oellerich M; Thervet E; Toenshoff B; Undre N; Weber LT; Westley IS; Mourad M
    Ther Drug Monit; 2009 Apr; 31(2):139-52. PubMed ID: 19177031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
    Widmer N; Bardin C; Chatelut E; Paci A; Beijnen J; Levêque D; Veal G; Astier A
    Eur J Cancer; 2014 Aug; 50(12):2020-36. PubMed ID: 24928190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relevance of therapeutic drug monitoring in plasma and erythrocytes in anti-cancer drug treatment.
    Dumez H; Guetens G; De Boeck G; Highley MS; Maes RA; van Oosterom AT; de Bruijn EA
    Clin Chem Lab Med; 2004; 42(11):1219-27. PubMed ID: 15576286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.